Your browser is no longer supported. Please, upgrade your browser.
Calithera Biosciences, Inc.
Index- P/E- EPS (ttm)-1.31 Insider Own1.00% Shs Outstand70.60M Perf Week-3.69%
Market Cap156.90M Forward P/E- EPS next Y-0.95 Insider Trans-0.32% Shs Float69.84M Perf Month-13.28%
Income-90.10M PEG- EPS next Q-0.28 Inst Own78.50% Short Float3.22% Perf Quarter-34.48%
Sales- P/S- EPS this Y31.00% Inst Trans2.86% Short Ratio2.38 Perf Half Y-44.27%
Book/sh1.45 P/B1.44 EPS next Y0.00% ROA-61.30% Target Price- Perf Year-70.77%
Cash/sh1.53 P/C1.36 EPS next 5Y- ROE-72.70% 52W Range2.03 - 7.34 Perf YTD-57.43%
Dividend- P/FCF- EPS past 5Y6.30% ROI- 52W High-71.53% Beta1.64
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low2.96% ATR0.12
Employees94 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)37.81 Volatility4.80% 5.61%
OptionableYes Debt/Eq0.00 EPS Q/Q18.90% Profit Margin- Rel Volume0.86 Prev Close2.08
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume947.33K Price2.09
Recom1.70 SMA20-4.30% SMA50-15.76% SMA200-41.93% Volume810,785 Change0.48%
Jan-05-21Downgrade SVB Leerink Outperform → Mkt Perform
Mar-27-20Initiated Jefferies Buy $6
Nov-19-19Initiated H.C. Wainwright Buy $7
May-30-19Resumed Citigroup Buy
Feb-16-18Upgrade Citigroup Neutral → Buy
Oct-05-17Initiated William Blair Outperform
Apr-03-17Resumed Leerink Partners Outperform
Mar-28-17Reiterated H.C. Wainwright Buy $10 → $14
Jan-24-17Upgrade Citigroup Sell → Neutral
Jan-05-17Initiated H.C. Wainwright Buy $9
Oct-25-16Initiated Citigroup Sell
Jul-24-15Initiated Citigroup Buy
May-07-21 03:30PM  
May-06-21 04:05PM  
Apr-30-21 07:00AM  
Apr-28-21 07:00AM  
Mar-29-21 01:40AM  
Mar-17-21 04:00AM  
Mar-16-21 04:06PM  
Mar-12-21 03:09PM  
Mar-10-21 07:05AM  
Mar-02-21 07:00AM  
Feb-22-21 07:00AM  
Jan-13-21 08:40AM  
Jan-11-21 05:03PM  
Jan-06-21 11:14AM  
Jan-05-21 10:59AM  
Jan-04-21 12:15PM  
Dec-31-20 04:55PM  
Dec-28-20 11:59PM  
Dec-14-20 12:03PM  
Dec-11-20 08:54AM  
Dec-02-20 07:05AM  
Nov-11-20 07:01AM  
Nov-09-20 07:00AM  
Nov-06-20 04:01PM  
Nov-05-20 04:06PM  
Nov-04-20 01:05PM  
Nov-02-20 04:07PM  
Oct-30-20 07:32AM  
Oct-29-20 07:01AM  
Oct-07-20 08:08AM  
Oct-02-20 07:01AM  
Sep-24-20 07:00AM  
Sep-11-20 09:58AM  
Sep-04-20 07:00AM  
Sep-02-20 07:01AM  
Aug-18-20 06:55AM  
Aug-11-20 08:00AM  
Aug-10-20 04:06PM  
Aug-03-20 07:01AM  
Jul-28-20 07:00AM  
Jul-14-20 07:00AM  
Jul-13-20 07:00AM  
Jul-06-20 08:05AM  
Jul-02-20 07:00AM  
Jun-02-20 07:00AM  
May-29-20 08:00AM  
May-27-20 07:01AM  
May-26-20 12:34AM  
May-18-20 11:30AM  
May-13-20 09:15AM  
May-11-20 12:00PM  
May-08-20 01:01PM  
May-07-20 04:05PM  
May-06-20 07:05AM  
May-01-20 09:57AM  
Apr-30-20 07:01AM  
Apr-20-20 04:05PM  
Apr-16-20 12:18AM  
Apr-15-20 04:01PM  
Apr-14-20 08:48AM  
Apr-13-20 11:14AM  
Apr-07-20 09:30AM  
Mar-30-20 05:15PM  
Mar-28-20 09:09AM  
Mar-11-20 04:10PM  
Mar-04-20 07:05AM  
Feb-19-20 07:05AM  
Jan-30-20 09:38AM  
Jan-13-20 07:07AM  
Jan-03-20 07:05AM  
Dec-13-19 02:46PM  
Dec-06-19 07:05AM  
Dec-05-19 07:05AM  
Dec-04-19 08:20PM  
Dec-02-19 11:38AM  
Nov-12-19 04:06PM  
Nov-05-19 08:01AM  
Nov-04-19 08:00AM  
Oct-19-19 09:23AM  
Oct-18-19 10:23AM  
Oct-07-19 09:54AM  
Oct-03-19 07:05AM  
Oct-01-19 04:05PM  
Sep-29-19 10:30AM  
Sep-28-19 02:30AM  
Sep-27-19 09:28AM  
Sep-26-19 06:05PM  
Sep-25-19 08:05AM  
Sep-19-19 10:06AM  
Sep-09-19 09:38PM  
Aug-28-19 08:00AM  
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor that is in Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and CB-708, an orally administered small molecule inhibitor of CD73, as well as CB-668, an inhibitor of the enzyme IL4I1. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Orford KeithChief Medical OfficerDec 16Sale6.002,44714,68211,094Dec 18 05:00 PM
BVF PARTNERS L P/IL10% OwnerMay 21Sale6.002,283,59813,701,588480,432May 26 05:52 PM